Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Reuters

2025/12/03

Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals plc has announced that pivotal Phase 3 results from the HERIZON-GEA-01 study evaluating Ziihera® (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), scheduled for January 8-10, 2026, in San Francisco. The late-breaking presentation will highlight data on Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab). According to the company, both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy. The combination with tislelizumab also showed statistically significant improvement in overall survival. The results will be presented during an oral abstract session on January 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF37575) on December 02, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588066976"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588066976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588066976?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588066976","market":"nz","top_or_hot":-1,"title":"Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced that pivotal Phase 3 results from the HERIZON-GEA-01 study evaluating Ziihera® (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), scheduled for January 8-10, 2026, in San Francisco. The late-breaking presentation will highlight data on Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab). According to the company, both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy. The combination with tislelizumab also showed statistically significant improvement in overall survival. The results will be presented during an oral abstract session on January 8, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF37575) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-03 05:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jazz Pharmaceuticals plc has announced that pivotal Phase 3 results from the HERIZON-GEA-01 study evaluating Ziihera® (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), scheduled for January 8-10, 2026, in San Francisco. The late-breaking presentation will highlight data on Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab). According to the company, both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy. The combination with tislelizumab also showed statistically significant improvement in overall survival. The results will be presented during an oral abstract session on January 8, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF37575) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2Ltc1P:1","article_id":"2588066976","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588066976","pubTimestamp":1764709536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jazz Pharmaceuticals plc has announced that pivotal Phase 3 results from the HERIZON-GEA-01 study evaluating Ziihera  combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium , scheduled for January 8-10, 2026, in San Francisco. The late-breaking presentation will highlight data on Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra . According to the company, both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy. The combination with tislelizumab also showed statistically significant improvement in overall survival. The results will be presented during an oral abstract session on January 8, 2026.Disclaimer: This new","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","JAZZ":"爵士制药","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Jazz Pharmaceuticals宣布Ziihera治疗HER2阳性胃食管癌的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer\n    \n\n        Jazz Pharmaceuticals plc has announced that pivotal Phase 3 results from the HERIZON-GEA-01 study evaluating Ziihera® (zanidatamab-hrii) combinations in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), scheduled for January 8-10, 2026, in San Francisco. The late-breaking presentation will highlight data on Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab). According to the company, both Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm of trastuzumab plus chemotherapy. The combination with tislelizumab also showed statistically significant improvement in overall survival. The results will be presented during an oral abstract session on January 8, 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF37575) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}